Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01384253
Title Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Areva Med LLC

ovarian cancer

breast cancer

peritoneum cancer

gastrointestinal system cancer

pancreatic cancer


212Pb-TCMC-Trastuzumab + Trastuzumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.